First relapsed childhood ALL Role of chemotherapy
|
|
- Earl Nichols
- 5 years ago
- Views:
Transcription
1 First relapsed childhood ALL Role of chemotherapy Thirachit Chotsampancharoen, M.D. Division of Pediatric Hematology/Oncology Department of Pediatrics Prince of Songkla University Hat-Yai, Songkhla 25 Oct 2018
2 Case scenario I 7 year-old girl with history of easy bruising and intermittent fever for 1 month WBC 18,000, Hb7, Plt 29,000 with 30% circulating blasts Bone marrow revealed acute lymphoblastic leukemia Immunophenotype: B-lineage Normal cytogenetics (46;XX), no blasts in the CNS (CNS-1) Enrolled on TPOG standard risk protocol and remission after induction, ongoing to maintenance phase Clinical and BM remission after complete of treatment (off therapy 1 year)
3 Case scenario I After complete of treatment (off therapy 1 year) She had easy bruising WBC 20,000, Hb 6, Plt 39,000 with 40% circulating blasts Bone marrow confirmed relapse B-lineage ALL with normal cytogenetics (46;XX), no blasts in the CNS (CNS-1) Others: WNL What should we do for this condition? Transplantation or Chemotherapy?
4 Treatment of childhood relapsed ALL Is HSCT only answer for childhood relapsed? Yes / No Is there any role of chemotherapy for relapsed? Yes / No
5 Outcome of treatment of newly diagnosed childhood ALL Outcome of non-treatment of newly diagnosed childhood ALL Pui C. Engl J Med 2006;354: Chotsampancharoen T. Acta Haematol 2018;140:203-8
6 Outcome of relapsed ALL Oskarsson T. Haematologica 2016;101:68-76 Rivera GK. Cancer 2005;103:368-76
7 Outcome of relapsed childhood ALL Oskarsson T. Haematologica 2016;101:68-76
8 HSCT versus Chemotherapy For children with ALL in second remission, BMT from HLA siblings results in fewer relapses and longer EFS than does chemotherapy Barrett AJ, N Engl J Med 1994;331:1253-8
9 HSCT versus Chemotherapy For children with relapsed ALL, BMT from HLA siblings results in longer EFS than Chemotherapy Boulad F, J Clin Oncol 1999;17:
10 HSCT versus Chemotherapy P> relapsed ALL in UK ALL R1 trail No significant difference in survival outcome between the donor and no donor groups (chemotherapy) There was the possibility of EFS benefit with HSCT, especially in patients with early relapsed Harrison G. Ann Oncol 2000;11:
11 Treatment of relapsed precursor-b ALL with chemotherapy: POG Study relapsed childhood ALL EFS for the whole group was 40 % at 8 years and not related to age at relapse, initial WBC, sex, or induction regimen EFS was significantly better in patients with a longer duration of CR1 regardless of whether the cut was made at 24 mo or 36 mo (p<.005) This study demonstrate no significant difference in EFS in chemotherapy alone (45%) or HSCT (50%) p= HSCT may improve the outcome of children with early marrow relapse but is of less value to patients with later marrow relapse or isolated CNS relapse Kelly ME, J Pediatr Hematol Oncol 2013;35:509-13
12 HSCT is superior than CT in all relapsed ALL? Homogeneous population in all childhood relapsed ALL?
13 Outcome for relapsed ALL BMT 38% v CT 30.7 % (p 0.423) River GK. Cancer 2005;103:368-76
14 Outcome for BM relapsed ALL The 5-year EFS with an late relapsed (> 36 months) was 42.6% v 12.5 % among children with early relapsed (< 36 months) The 5-year EFS were 28% for B blast V 5% for T blast cell lineages, respectively. Rivera GK. Cancer 2005;103:368-76
15 Site of relapsed isolated CNS isolated BM isolated testes Gaynon PS. Cancer 1998;82:
16 Site of relapsed Chessels JM, Br J Hematol1998;102:
17 Risk classifications of relapsed ALL Homogeneous population in relapsed ALL? Timing of relapsed- strong evidence for clonal resistant Immunophenotype of leukemic cell- B lineage Site of relapsed Locatelli F, Blood 2012 Locatelli F, Curr Opin Oncol 2013
18 Berlin Frankfurt Munster (BFM) classification Very early relapse: < 18 months from diagnosis (during treatment) Early relapse:>18 months from diagnosis, but < 6 months from treatment discontinuation Late relapse: >6 months from stop treatment COG classification Early relapse <36 months from initial diagnosis Late marrow relapse >36 months from initial diagnosis Locatelli F, Curr Opin Oncol 2013
19 Berlin Frankfurt Munster (BFM) classification Locatelli F, Curr Opin Oncol 2013
20 Berlin Frankfurt Munster (BFM) classification Early and T Locatelli F, Curr Opin Oncol 2013
21 Risk classification of relapsed ALL Locatelli F, Blood 2012
22 Risk classifications of relapsed ALL Timing of relapsed Immunophenotype of leukemic cell Site of relapsed More??? Locatelli F, Blood 2012 Locatelli F, Curr Opin Oncol 2013
23 Outcome of children with first marrow relapse of acute lymphoblastic leukemia: COG study Timing MRD EFS by timing and MRD Raetz EA. J Clin Oncol 2008;26:3971-8
24 Outcome of children with first marrow relapse of acute lymphoblastic leukemia: COG study Early marrow relapse Late marrow relapse B: Early marrow relapse: 12-month EFS 67% versus 42% for MRD-negative versus - positive patients. C: Late marrow relapse: 12-month EFS 86% versus 77% in MRD-negative versus - positive patients Raetz EA. J Clin Oncol 2008;26:3971-8
25 Outcome of children with first marrow relapse of acute lymphoblastic leukemia: COG study MRD was measured by flow cytometry MRD 0.01% v MRD >0.01% Raetz EA. J Clin Oncol 2008;26:3971-8
26 Risk classifications of relapsed ALL Timing of relapsed Immunophenotype of leukemic cell Site of relapsed Isolated bone marrow Combined Isolated extramedullary (CNS, testicular) Minimal residual disease (MRD) Locatelli F, Blood 2012 Locatelli F, Curr Opin Oncol 2013
27 Outcome of relapsed ALL: results of trial ALL-REZ BFM 90 A : early isolated bone marrow or combined relapses B : late isolated or combined BM relapses C : isolated extramedullary relapses Tallen G, J Clin Oncol 2010;28:
28 Tallen G, J Clin Oncol 2010;28:
29 Outcome of relapsed ALL: results of trial ALL-REZ BFM 90 HSCT was individually considered for HR patients EFS were significantly higher after HSCT than after chemotherapy alone in HR No benefit in intermediate-risk patients Tallen G, J Clin Oncol 2010;28:
30 Long-term results of trial ALL-REZ BFM 95/96 in relapsed childhood ALL Eckert C, European J Cancer 2013;49:
31 Long-term results of trial ALL-REZ BFM 95/96 in relapsed childhood ALL MRD after RE-induction is the strongest predictor of prognosis in intermediate risk relapsed ALL Eckert C, European J Cancer 2013;49:
32 Long-term results of trial ALL-REZ BFM 95/96 in relapsed childhood ALL Transplant Non transplant Influence of HSCT v CT on prognosis of intermediate risk relapses with molecular good and poor response to induction Eckert C, European J Cancer 2013;49:
33 HSCT versus Chemotherapy IR HR Borgmann A, Blood 2003;101;3835-9
34 HSCT versus Chemotherapy IR HSCT CT P = Borgmann A, Blood 2003;101;3835-9
35 Pathway Parker C, Lancet 2010;376:
36 Key points 1. HSCT is not complete answer for all relapsed childhood ALL 2. Risk stratified Standard, Intermediate and High-risk groups Timing of relapsed Site of relapse Leukemic cell immunophenotype MRD 3. Even HSCT is the good choice for high-risk relapsed ALL but the outcome of HSCT in high risk is not adequate answer 4. New modality strategies 5. HSCT had a price to pay
37 New modalities treatment relapsed childhood ALL Bhojwani D, Pui CH, Lancet Oncol 2013;14:205-17
38 Case scenario Late relapse B-lineage ALL- intermediate risk- BFM BFM-REZ protocol re-induction- CR, MRD after 3 course < 0.01% and continue for maintenance phase No HSCT Continue remission for 8 years after complete treatment of relapsed
39 Treatment of Relapsed ALL Is HSCT only answer for childhood relapsed? No Is there any role of chemotherapy for relapsed? Yes
40 Next Samart prospective trial: HSCT in relapsed ALL
41 Questions
Improved outcome in childhood ALL with intensive consolidation and hematopoietic stem cell transplant
VOLUME 45 ㆍ NUMBER 2 ㆍ June 2010 THE KOREAN JOURNAL OF HEMATOLOGY ORIGINAL ARTICLE Improved outcome in childhood ALL with intensive consolidation and hematopoietic stem cell transplant Jeong A Park 1,
More informationMRD in ALL: Correct interpretation in clinical practice. Deepak Bansal Prof., Pediatric Hematology-Oncology unit PGIMER, Chandigarh
MRD in ALL: Correct interpretation in clinical practice Deepak Bansal Prof., Pediatric Hematology-Oncology unit PGIMER, Chandigarh Minimal residual disease Subclinical level of residual leukemia Below
More informationStandard risk ALL (and its exceptions
Mahshid Mehdizadeh Standard risk ALL (and its exceptions WBC at diagnosis below 50 109/L - age 1 year - no central nervous system (CNS) involvement - ETV6/RUNX1 positivity - MRD at Day
More informationControversies in Hematology: Case-Based Discussion. Acute leukemia in Adolescents and Young adults October 2018, Chiang Mai Thailand
Controversies in Hematology: Case-Based Discussion Acute leukemia in Adolescents and Young adults 25-26 October 2018, Chiang Mai Thailand Associate Prof. Adisak Tantiworawit, MD Division of Hematology,
More informationCorrelation of Sex and Remission of Acute Lymphoblastic Leukemia-L1 (ALL-L1) in Children
International Journal of Clinical and Experimental Medical Sciences 2015; 1(2): 11-15 Published online July 6, 2015 (http://www.sciencepublishinggroup.com/j/ijcems) doi: 10.11648/j.ijcems.20150102.12 Correlation
More informationAcute Lymphoblastic Leukemia (ALL) Ryan Mattison, MD University of Wisconsin March 2, 2010
Acute Lymphoblastic Leukemia (ALL) Ryan Mattison, MD University of Wisconsin March 2, 2010 ALL Epidemiology 20% of new acute leukemia cases in adults 5200 new cases in 2007 Most are de novo Therapy-related
More informationETP - Acute Lymphoblastic Leukaemia
ETP - Acute Lymphoblastic Leukaemia Dr Sally Campbell - Royal Children s Hospital Melbourne 24 February 2017 T-ALL 12-15% of all newly diagnosed ALL cases in pediatrics are T-ALL T-ALL behaves differently
More informationACUTE LYMPHOBLASTIC LEUKEMIA
ACUTE LYMPHOBLASTIC LEUKEMIA YOUNG ADULT PATIENT Highlights clonoseq Tracking (MRD) Testing in the peripheral blood revealed early signs of relapse post-transplant Patient achieved remission after CAR-T
More informationH Schroeder 1, G Gustafsson 2, UM Saarinen-Pihkala 3, A Glomstein 4, G Jonmundsson 5, K Nysom 6, O Ringdén 7 and L Mellander 8.
Bone Marrow Transplantation, (1999) 23, 555 560 1999 Stockton Press All rights reserved 0268 3369/99 $12.00 http://www.stockton-press.co.uk/bmt Allogeneic bone marrow transplantation in second remission
More informationAcute Lymphoblastic and Myeloid Leukemia
Acute Lymphoblastic and Myeloid Leukemia Pre- and Post-Disease Form Acute Lympoblastic Leukemia Mary Eapen MD, MS Acute Lymphoblastic Leukemia SEER Age-adjusted incidence rate 1.6 per 100,000 men and women
More informationSummary. Olga Zając, Katarzyna Derwich, Katarzyna Stefankiewicz, Jacek Wachowiak. Rep Pract Oncol Radiother, 2007; 12(5):
Rep Pract Oncol Radiother, 2007; 12(5): 283-288 Preliminary Communication Received: 2007.03.27 Accepted: 2007.07.24 Published: 2007.10.18 Authors Contribution: A Study Design B Data Collection C Statistical
More informationMANAGEMENT OF ACUTE LYMPHOBLASTIC LEUKEMIA. BY Dr SUBHASHINI 1 st yr PG DEPARTMENT OF PEDIATRICS
MANAGEMENT OF ACUTE LYMPHOBLASTIC LEUKEMIA BY Dr SUBHASHINI 1 st yr PG DEPARTMENT OF PEDIATRICS Introduction The management of ALL, the most common childhood malignancy (1/3 rd of all malignancy), has
More informationJohann Hitzler, MD, FRCPC, FAAP Jacqueline Halton, MD, FRCPC Jason D. Pole, PhD
Photo by Tynan Studio Johann Hitzler, MD, FRCPC, FAAP Jacqueline Halton, MD, FRCPC Jason D. Pole, PhD 96 Atlas of Childhood Cancer in Ontario (1985-2004) Chapter 6: Leukemia 6 Leukemia Atlas of Childhood
More informationProphylactic Cranial Irradiation in Acute Lymphoblastic Leukemia: Is there still an indication? Celine Bicquart, MD Radiation Medicine May 5, 2010
Prophylactic Cranial Irradiation in Acute Lymphoblastic Leukemia: Is there still an indication? Celine Bicquart, MD Radiation Medicine May 5, 2010 Outline Epidemiology Risk-groups Background & Rationale
More informationRisk Stratification in Childhood Leukemia
Risk Stratification in Childhood Leukemia Why is risk stratification important? Toxicities Deepa Bhojwani, MD May 11, 2018 To determine intensity of therapy - When to intensify therapy - When to de-intensify
More informationElisabeth Koller 3rd Medical Dept., Center for Hematology and Oncology, Hanusch Hospital, Vienna, Austria
Elisabeth Koller 3rd Medical Dept., Center for Hematology and Oncology, Hanusch Hospital, Vienna, Austria Incidence Diagnosis Prognostic factors Treatment Induction therapy - HSCT Indications for HSCT
More informationFactors influencing survival after relapse from acute lymphoblastic leukemia: a Children s Oncology Group study
(2008) 22, 2142 2150 & 2008 Macmillan Publishers Limited All rights reserved 0887-6924/08 $32.00 www.nature.com/leu ORIGINAL ARTICLE Factors influencing survival after relapse from acute lymphoblastic
More informationCurrent Indications of Bone Marrow Transplantation (BMT) in Pediatric Malignant Conditions; a Review
EXPERT OPINION Current Indications of Bone Marrow Transplantation (BMT) in Pediatric Malignant Conditions; a Review Chi-Kong Li Department of Pediatrics, Prince of Wales Hospital, The Chinese University
More informationInstructions for Chronic Lymphocytic Leukemia Post-HSCT Data (Form 2113)
Instructions for Chronic Lymphocytic Leukemia Post-HSCT Data (Form 2113) This section of the CIBMTR Forms Instruction Manual is intended to be a resource for completing the CLL Post-HSCT Data Form. E-mail
More informationPediatric Acute Leukemia: The Effect of Prognostic Factors on Clinical Outcomes at Phramongkutklao Hospital, Bangkok, Thailand
Pediatric Acute Leukemia: The Effect of Prognostic Factors on Clinical Outcomes at Phramongkutklao Hospital, Bangkok, Thailand Piya Rujkijyanont MD*, Suphathida Kaewinsang MD*, Chalinee Monsereenusorn
More informationThe probability of curing children with acute. brief report
brief report Hematopoietic stem cell transplant versus chemotherapy plus tyrosine kinase inhibitor in the treatment of pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL) Khadra
More informationPhiladelphia chromosome-positive acute lymphoblastic leukemia in childhood
Review article DOI: 10.3345/kjp.2011.54.3.106 Korean J Pediatr 2011;54(3):106-110 Philadelphia chromosome-positive acute lymphoblastic leukemia in childhood Hong Hoe Koo, M.D., Ph.D. Department of Pediatrics,
More informationMUD SCT for Paediatric AML?
7 th South African Symposium on Haematopoietic Stem Cell Transplantation MUD SCT for Paediatric AML? Alan Davidson Haematology / Oncology Service Red Cross Children s Hospital THE SCENARIO A 10 year old
More informationMinimal residual disease (MRD) in AML; coming of age. Dr. Mehmet Yılmaz Gaziantep University Medical School Sahinbey Education and Research hospital
Minimal residual disease (MRD) in AML; coming of age Dr. Mehmet Yılmaz Gaziantep University Medical School Sahinbey Education and Research hospital 1. The logistics of MRD assessment in AML 2. The clinical
More informationIndication for unrelated allo-sct in 1st CR AML
Indication for unrelated allo-sct in 1st CR AML It is time to say! Decision of allo-sct: factors to be considered Cytogenetic risk status Molecular genetics FLT3; NPM1, CEBPA. Response to induction Refractoriness
More informationAcute Leukemia. Sebastian Giebel. Geneva 03/04/
Acute Leukemia (including ALL) Sebastian Giebel Geneva 03/04/2012 www.ebmt.org Acute leukemias: EBMT survey 2 AML: EBMT survey Gratwohl A, et al. Bone Marrow Transplant 2009 3 Acute leukemias: INCIDENCE
More informationAppendix 6: Indications for adult allogeneic bone marrow transplant in New Zealand
Appendix 6: Indications for adult allogeneic bone marrow transplant in New Zealand This list provides indications for the majority of adult BMTs that are performed in New Zealand. A small number of BMTs
More informationMS.4/ Acute Leukemia: AML. Abdallah Al Abbadi.MD.FRCP.FRCPath Feras Fararjeh MD
MS.4/ 27.02.2019 Acute Leukemia: AML Abdallah Al Abbadi.MD.FRCP.FRCPath Feras Fararjeh MD Case 9: Acute Leukemia 29 yr old lady complains of fever and painful gums for 1 week. She developed easy bruising
More informationBone Marrow Transplantation in Myelodysplastic Syndromes. An overview for the Myelodysplasia Support Group of Ottawa
Bone Marrow Transplantation in Myelodysplastic Syndromes An overview for the Myelodysplasia Support Group of Ottawa Objectives Provide brief review of marrow failure Re emphasize the importance of predictions
More informationMinimal residual disease: optimal methods, timing, and clinical relevance for an individual patient
DYNAMIC DISCOVERIES AND DIRECTIONS IN PEDIATRIC LEUKEMIAS Minimal residual disease: optimal methods, timing, and clinical relevance for an individual patient Martin Schrappe 1 1 Department of Pediatrics
More informationClinical characteristics and prognosis of pediatric patients with B cell acute lymphoblastic leukemia relapse
ONCOLOGY LETTERS 16: 2929-2934, 2018 Clinical characteristics and prognosis of pediatric patients with B cell acute lymphoblastic leukemia relapse XIAOHONG ZHANG 1*, HAIXIA WU 2*, HONG FAN 3, BAIFANG SU
More informationTherapeutic Advances in Treatment of Aplastic Anemia. Seiji Kojima MD. PhD.
Therapeutic Advances in Treatment of Aplastic Anemia Seiji Kojima MD. PhD. Department of Pediatrics Nagoya University Graduate School of Medicine Chairman of the Severe Aplastic Anemia Working Party Asia-Pacific
More informationAdult ALL: NILG experience
Adult ALL: NILG experience R Bassan USC Ematologia, Ospedali Riuniti, Bergamo SIE Interregionale, Padova 12 5 2011 Now and then Northern Italy Leukemia Group 2000-10 Prospective clinical trials 09/00 10/07
More informationStem cell transplantation for patients with AML in Republic of Macedonia: - 15 years of experience -
Stem cell transplantation for patients with AML in Republic of Macedonia: - 15 years of experience - R E S E A R C H A S S O C I A T E P R O F. D - R Z L A T E S T O J A N O S K I Definition Acute myeloid
More informationLEUKAEMIA and LYMPHOMA. Dr Mubarak Abdelrahman Assistant Professor Jazan University
LEUKAEMIA and LYMPHOMA Dr Mubarak Abdelrahman Assistant Professor Jazan University OBJECTIVES Identify etiology and epidemiology for leukemia and lymphoma. Discuss common types of leukemia. Distinguish
More informationN Engl J Med Volume 373(12): September 17, 2015
Review Article Acute Myeloid Leukemia Hartmut Döhner, M.D., Daniel J. Weisdorf, M.D., and Clara D. Bloomfield, M.D. N Engl J Med Volume 373(12):1136-1152 September 17, 2015 Acute Myeloid Leukemia Most
More informationCan ALL be managed without chemotherapy/transplant? (Position: NO) D.Hoelzer J.W.Goethe University Frankfurt
Can ALL be managed without chemotherapy/transplant? (Position: NO) D.Hoelzer J.W.Goethe University Frankfurt Barcelona, September 2012 First report of Monotherapy in childhood ALL 10/16 children with acute
More informationConsolidation and maintenance therapy for transplant eligible myeloma patients
Consolidation and maintenance therapy for transplant eligible myeloma patients Teeraya Puavilai, M.D. Division of Hematology, Department of Medicine Faculty of Medicine Ramathibodi Hospital Mahidol University
More informationPattern of relapse in paediatric acute lymphoblastic leukaemia in a tertiary care unit
961 ORIGINAL ARTICLE Pattern of relapse in paediatric acute lymphoblastic leukaemia in a tertiary care unit Emad Uddin Siddiqui, 1 Sayyeda Ghazala Kazi, 2 Muhammad Irfan Habib, 3 Khalid Mehmood Ahmed Khan,
More information2011: ALL Pre-HCT. Subsequent Transplant
2011: ALL Pre-HCT The Acute Lymphoblastic Leukemia Pre-HCT Data Form is one of the Comprehensive Report Forms. This form captures ALL-specific pre-hct data such as: the recipient s hematologic and cytogenetic
More informationEvolving Targeted Management of Acute Myeloid Leukemia
Evolving Targeted Management of Acute Myeloid Leukemia Jessica Altman, MD Robert H. Lurie Comprehensive Cancer Center of Northwestern University Learning Objectives Identify which mutations should be assessed
More informationThe Role of Prognostic Features in the Treatment of Childhood Acute Lymphoblastic Leukemia
The Role of Prognostic Features in the Treatment of Childhood Acute Lymphoblastic Leukemia ALISON M. FRIEDMANN, HOWARD J. WEINSTEIN Massachusetts General Hospital, Division of Pediatric Hematology/Oncology,
More informationAbstract 861. Stein AS, Topp MS, Kantarjian H, Gökbuget N, Bargou R, Litzow M, Rambaldi A, Ribera J-M, Zhang A, Zimmerman Z, Forman SJ
Treatment with Anti-CD19 BiTE Blinatumomab in Adult Patients With Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (R/R ALL) Post-Allogeneic Hematopoietic Stem Cell Transplantation Abstract
More informationPacharapan Surapolchai, MD Associate Professor Department of Pediatrics, Faculty of Medicine, Thammasat University, Thailand October 2018
Pacharapan Surapolchai, MD Associate Professor Department of Pediatrics, Faculty of Medicine, Thammasat University, Thailand October 2018 Outline Case study Introduction of Current management of infantile
More informationHigh-Risk Pediatric Acute Lymphoblastic Leukemia: To Transplant or Not to Transplant?
High-Risk Pediatric Acute Lymphoblastic Leukemia: To Transplant or Not to Transplant? Michael A. Pulsipher, 1 Christina Peters, 2 Ching-Hon Pui 3 Because survival with both chemotherapy and allogeneic
More informationMultiparameter flow cytometry can be used to
Minimal residual disease testing in Acute Leukemia Anjum Hassan MD Assistant Professor of Pathology and Immunology, Director FISH laboratory in Anatomic Pathology, Washington University in St Louis, School
More informationProtocol. Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia
Hematopoietic Cell Transplantation for Acute Lymphoblastic (80132) Medical Benefit Effective Date: 07/01/14 Next Review Date: 07/18 Preauthorization Yes Review Dates: 04/07, 05/08, 05/09, 03/10, 03/11,
More informationPediatric Acute Lymphoblastic Leukemia. Highlights of ASH 2015
Pediatric Acute Lymphoblastic Leukemia Highlights of ASH 2015 Thai National Protocol Outcomes Outcome is very dependent on treatment Patient s compliance Treatment of ALL Induction Intensification Maintenance
More informationAcute myeloid leukemia: prognosis and treatment. Dimitri A. Breems, MD, PhD Internist-Hematoloog Ziekenhuis Netwerk Antwerpen Campus Stuivenberg
Acute myeloid leukemia: prognosis and treatment Dimitri A. Breems, MD, PhD Internist-Hematoloog Ziekenhuis Netwerk Antwerpen Campus Stuivenberg Patient Female, 39 years History: hypothyroidism Present:
More informationTherapy-related MDS/AML with KMT2A (MLL) Rearrangement Following Therapy for APL Case 0328
Therapy-related MDS/AML with KMT2A (MLL) Rearrangement Following Therapy for APL Case 0328 Kenneth N. Holder, Leslie J. Greebon, Gopalrao Velagaleti, Hongxin Fan, Russell A. Higgins Initial Case: Clinical
More informationWHAT ARE PAEDIATRIC CANCERS
WHAT ARE PAEDIATRIC CANCERS INTRODUCTION Childhood cancers are RARE 0.5% of all cancers in the West Overall risk that a child will develop cancer during first 15 years of life is 1 in 450 and 1 in 600
More informationUNTHSC Scholarly Repository. University of North Texas Health Science Center
University of North Texas Health Science Center UNTHSC Scholarly Repository Theses and Dissertations Winter 12-2009 Retrospective Analysis of Survival and Treatment Related Mortality Following a Myeloablative
More informationJ Clin Oncol 26: by American Society of Clinical Oncology INTRODUCTION
V O L U M E 2 6 N U M B E R 1 8 J U N E 2 0 2 0 0 8 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Minimal Residual Disease Values Discriminate Between Low and High Relapse Risk in Children With
More informationTargeting CD20 and CD22 in B-cell ALL Daniel J. DeAngelo, MD, PhD
Targeting CD20 and CD22 in B-cell ALL Daniel J. DeAngelo, MD, PhD Harvard/Dana-Farber Cancer Institute Boston, MA Disclosures for Daniel J. DeAngelo, MD, PhD Royalty Receipt of intellectual property/ Patent
More informationMyelodysplasia/Myeloproliferative Neoplasms (MDS/MPN) Post-HCT Data
Instructions for Myelodysplasia/Myeloproliferative Neoplasms (MDS/MPN) Post-HCT Data (Form 2114) This section of the CIBMTR Forms Instruction Manual is intended to be a resource for completing the Myelodysplasia/Myeloproliferative
More informationAll patients with FLT3 mutant AML should receive midostaurin-based induction therapy. Not so fast!
All patients with FLT3 mutant AML should receive midostaurin-based induction therapy Not so fast! Harry P. Erba, M.D., Ph.D. Professor, Internal Medicine Director, Hematologic Malignancy Program University
More informationA lthough central nervous system (CNS) prophylaxis in patients with ALL has
Original Article Central nervous system relapse prophylaxis in acute lymphoblastic leukemia (ALL) intrathecal chemotherapy with and without cranial irradiation Ahmad Tamaddoni (MD) 1 Hassan Mahmodi Nesheli
More informationOriginal article. Key words: Lymphoblastic leukemia, Acute, Childhood, Minimal residual disease, Flow cytometry
Original article DOI: 10.5/kjp.2010.5.11.957 Korean J Pediatr 2010;5(11):957-96 Prognostic significance of minimal residual disease detected by a simplified flow cytometric assay during remission induction
More informationMast Cell Disease Case 054 Session 7
Mast Cell Disease Case 054 Session 7 Rodney R. Miles, M.D., Ph.D. Lauren B. Smith, M.D. Cem Akin, M.D. Diane Roulston,, Ph.D. Charles W. Ross, M.D. Departments of Pathology and Internal Medicine University
More informationAdult Acute leukemia. Matthew Seftel. August
Adult Acute leukemia Matthew Seftel August 21 2007 mseftel@cancercare.mb.ca Principles 3 cases Diagnosis and classification of acute leukemia (AL) Therapy Emergencies Remission induction BMT Complications
More informationReduced-intensity Conditioning Transplantation
Reduced-intensity Conditioning Transplantation Current Role and Future Prospect He Huang M.D., Ph.D. Bone Marrow Transplantation Center The First Affiliated Hospital Zhejiang University School of Medicine,
More informationExtramedullary precursor T-lymphoblastic transformation of CML at presentation
Extramedullary precursor T-lymphoblastic transformation of CML at presentation Neerja Vajpayee, Constance Stein, Bernard Poeisz & Robert E. Hutchison Clinical History 30 year old man presented to the emergency
More informationPrognostic significance of leukopenia in childhood acute lymphoblastic leukemia
ONCOLOGY LETTERS 7: 1169-1174, 2014 Prognostic significance of leukopenia in childhood acute lymphoblastic leukemia YUSUKE SHIOZAWA 1, JUNKO TAKITA 1,2, MOTOHIRO KATO 3, MANABU SOTOMATSU 4, KATSUYOSHI
More informationHematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia
Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia Policy Number: 8.01.32 Last Review: 7/2018 Origination: 7/2002 Next Review: 7/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue
More informationPDF of Trial CTRI Website URL -
Clinical Trial Details (PDF Generation Date :- Wed, 19 Dec 2018 02:45:15 GMT) CTRI Number Last Modified On 25/12/2017 Post Graduate Thesis Type of Trial Type of Study Study Design Public Title of Study
More informationMinimal residual disease is an important predictive factor of outcome in children with relapsed high-risk acute lymphoblastic leukemia
ORIGINAL ARTICLE (2008) 22, 2193 2200 & 2008 Macmillan Publishers Limited All rights reserved 0887-6924/08 $32.00 www.nature.com/leu Minimal residual disease is an important predictive factor of outcome
More informationJ Clin Oncol 29: by American Society of Clinical Oncology INTRODUCTION
VOLUME 29 NUMBER 3 JANUARY 20 2011 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Response-Guided Induction Therapy in Pediatric Acute Myeloid Leukemia With Excellent Remission Rate Jonas Abrahamsson,
More informationShould patients with higher risk MDS (or AML in «early relapse») proceed directly to allo SCT without prior chemotherapy?
Should patients with higher risk MDS (or AML in «early relapse») proceed directly to allo SCT without prior chemotherapy? Pierre Fenaux Cohem 2012 Barcelona Should patients with higher risk MDS (or AML
More informationLOW INCIDENCE OF CNS RELAPSE WITH CRANIAL RADIOTHERAPY AND INTRATHECAL METHOTREXATE IN ACUTE LYMPHOBLASTIC LEUKEMIA
Original Articles LOW INCIDENCE OF CNS RELAPSE WITH CRANIAL RADIOTHERAPY AND INTRATHECAL METHOTREXATE IN ACUTE LYMPHOBLASTIC LEUKEMIA N.S. Raje, S.J. Vaidya, G. Kapoor, S.K. Pai, C.N. Nair, P.A. Kurkure,
More informationMULTIPLE MYELOMA. The clonoseq Assay can predict progressionfree survival in myeloma patients
MULTIPLE MYELOMA With current therapies, complete response (CR) is reached in 3-5% of multiple myeloma () patients. 1 However, most of these patients will experience relapse due to the persistence of residual
More informationDepartment of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, Texas; 2 Sunesis Pharmaceuticals, Inc, South San Francisco
Phase I/II Study of Vosaroxin and Decitabine in Newly Diagnosed Older Patients with Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS) Naval Daver 1, Hagop Kantarjian 1, Guillermo
More informationAcute leukemia & agressive lymphoma in children
Acute leukemia & agressive lymphoma in children Barbara De Moerloose Dept. Pediatric Hematology-Oncology and Stem Cell Transplantation Ghent University Hospital barbara.demoerloose@uzgent.be * Childhood
More informationOutcome of acute leukemia patients with central nervous system (CNS) involvement treated with total body or CNS irradiation before transplantation
Original Article Page 1 of 9 Outcome of acute leukemia patients with central nervous system (CNS) involvement treated with total body or CNS irradiation before transplantation Wen-Han Kuo 1, Yu-Hsuan Chen
More informationTools for MRD in AML: flow cytometry
ACUTE MYELOID LEUKEMIA MEETING Ravenna - October 27, 2017 Tools for MRD in AML: flow cytometry Francesco Buccisano Can MRD improve outcome determina3on? No. of leukemic cells 10 12 10 10 10 8 10 6 10 4
More informationIsolated Testicular Relapse in Acute Lymphoblastic Leukemia - Effective Treatment with the Modified CCG-112 Protocol
Original Article Isolated Testicular Relapse in Acute Lymphoblastic Leukemia - Effective Treatment with the Modified CCG-112 Protocol Goyal Shama, Bhagwat Roshni, Pai Suresh K, Kurkure Purna A, Nair Chandrika
More informationEarly Clearance of Peripheral Blood Blasts Predicts Response to Induction Chemotherapy in Acute Myeloid Leukemia
Early Clearance of Peripheral Blood Blasts Predicts Response to Induction Chemotherapy in Acute Myeloid Leukemia Martha Arellano, MD 1 ; Suchita Pakkala, MD 1 ; Amelia Langston, MD 1 ; Mourad Tighiouart,
More informationby S.M. Ng, H.P. Lin, W.A. Arif n, A.K. Zainab, S.K. Lam and L.L. Chan Department of Paediatrics, University Hospital, Kuala Lumpur 59100, Malaysia
Age, Sex, Haemoglobin Level, and White Cell Count at Diagnosis are Important Prognostic Factors in Children with Acute Lymphoblastic Leukemia Treated with BFM-type Protocol by S.M. Ng, H.P. Lin, W.A. Arif
More informationCASE REPORT. Abstract. Introduction. Case Reports
CASE REPORT Two Elderly Patients with Philadelphia Chromosome Positive Mixed Phenotype Acute Leukemia Who Were Successfully Treated with Dasatinib and Prednisolone Hiroyuki Takata 1, Taichi Ikebe 1, Hitohiro
More informationMS.4/ 1.Nov/2015. Acute Leukemia: AML. Abdallah Abbadi
MS.4/ 1.Nov/2015. Acute Leukemia: AML Abdallah Abbadi Case 9: Acute Leukemia 29 yr old lady complains of fever and painful gums for 1 week. She developed easy bruising and hemorrhagic spots on her trunk
More informationPhiladelphia-positive Acute Lymphoblastic Leukemia
Philadelphia-positive Acute Lymphoblastic Leukemia Nicolas Boissel Service d Hématologie Unité Adolescents et Jeunes Adultes Hôpital Saint-Louis, Paris Ph+ acute lymphoblastic leukemia DR+, CD19+, CD22+,
More informationHaploidentical Transplantation today: and the alternatives
Haploidentical Transplantation today: and the alternatives Daniel Weisdorf MD University of Minnesota February, 2013 No matched sib: where to look? URD donor requires close HLA matching and 3-12 weeks
More informationA 34-year old women came because of abdominal discomfort. Vital sign was stable. Spleen tip was palpable.
1 Case 1 A 34-year old women came because of abdominal discomfort. Vital sign was stable. Spleen tip was palpable. CBC and bone marrow aspiration and biopsy were done. Chromosome study showed she had t(9;22)
More informationPersonalized Therapy for Acute Myeloid Leukemia. Patrick Stiff MD Loyola University Medical Center
Personalized Therapy for Acute Myeloid Leukemia Patrick Stiff MD Loyola University Medical Center 708-327-3216 Major groups of Mutations in AML Targets for AML: Is this Achievable? Chronic Myeloid Leukemia:
More informationAcute Lymphoblastic Leukaemia Guidelines
Acute Lymphoblastic Leukaemia Guidelines Approved by Pathway Board for Haematological Malignancies Coordinating author: Adele Fielding, Royal Free London NHS Trust Date of issue: 12.03.2015 Version number:
More informationAcute myeloid leukemia. M. Kaźmierczak 2016
Acute myeloid leukemia M. Kaźmierczak 2016 Acute myeloid leukemia Malignant clonal disorder of immature hematopoietic cells characterized by clonal proliferation of abnormal blast cells and impaired production
More informationCorporate Medical Policy. Policy Effective February 23, 2018
Corporate Medical Policy Genetic Testing for FLT3, NPM1 and CEBPA Mutations in Acute File Name: Origination: Last CAP Review: Next CAP Review: Last Review: genetic_testing_for_flt3_npm1_and_cebpa_mutations_in_acute_myeloid_leukemia
More informationCase 1. Sa A.Wang, MD UT MD Anderson Cancer Center Houston, TX
Case 1 Sa A.Wang, MD UT MD Anderson Cancer Center Houston, TX Disclosure of Relevant Financial Relationships The USCAP requires that anyone in a position to influence or control the content of all CME
More informationImpact of Day 14 Bone Marrow Biopsy on Re-Induction Decisions and Prediction of a Complete Response in Acute Myeloid Leukemia Cases
DOI:10.22034/APJCP.2018.19.2.421 RESEARCH ARTICLE Editorial Process: Submission:08/01/2017 Acceptance:12/09/2017 Impact of Day 14 Bone Marrow Biopsy on Re-Induction Decisions and Prediction of a Complete
More informationTCF3 breakpoints of TCF3-PBX1 (patients 1a 5a) and TCF3-HLF (patients 6a 9a and11a) translocations.
Supplementary Figure 1 TCF3 breakpoints of TCF3-PBX1 (patients 1a 5a) and TCF3-HLF (patients 6a 9a and11a) translocations. The CpG motifs closest to the breakpoints are highlighted in red boxes and the
More informationSUPPLEMENTAL APPENDIX
SUPPLEMENTAL APPENDIX Table of Contents 1. Supplemental Tables 2. Supplemental Figures Nature Medicine: doi:1.138/nm.4441 Supplemental Table 1. Baseline Characteristics of Patients Treated with anti-cd22
More informationAutologous versus Allogeneic Unrelated Donor Transplantation for Acute Lymphoblastic Leukemia: Comparative Toxicity and Outcomes
Biology of Blood and Marrow Transplantation 8:213-220 (2002) 2002 American Society for Blood and Marrow Transplantation ASBMT Autologous versus Allogeneic Unrelated Donor Transplantation for Acute Lymphoblastic
More informationModule 3: Multiple Myeloma Induction and Transplant Strategies Treatment Planning
Module 3: Multiple Myeloma Induction and Transplant Strategies Treatment Planning Challenge Question: Role of Autologous Stem Cell Transplant Which of the following is true about eligibility for high-dose
More informationDisclosures of: Emanuele Angelucci
Company name Novartis Disclosures of: Emanuele Angelucci Research support Employee Consultant Stockholder Speakers bureau Advisory board Chair of TELESTO pro Other EBMT 2012 Educational Session Haemoglobinopathy
More informationINTERFANT-06 INTERNATIONAL COLLABORATIVE TREATMENT PROTOCOL FOR INFANTS UNDER ONE YEAR WITH ACUTE LYMPHOBLASTIC OR BIPHENOTYPIC LEUKEMIA
INTERFANT-06 INTERNATIONAL COLLABORATIVE TREATMENT PROTOCOL FOR INFANTS UNDER ONE YEAR WITH ACUTE LYMPHOBLASTIC OR BIPHENOTYPIC LEUKEMIA Participating groups: DCOG (the Netherlands) BFM-G (Germany) CORS
More informationDr Prashant Tembhare
Dr Prashant Tembhare docprt@gmail.com FCM very powerful technology in Identification and characterization of neoplastic plasma cells as it allows - simultaneous assessment of multiple antigens large numbers
More informationLondon Cancer ALL guidelines
London Cancer ALL guidelines Page 1 of 7 CONTENTS OVERVIEW - main points in ALL management... 3 AGE-SPECIFIC THERAPEUTIC APPROACHES... 4 SPECIFIC THERAPEUTIC PROBLEMS... 5 SUPPORTIVE CARE... 6 PATIENTS
More informationWe are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 3,500 108,000 1.7 M Open access books available International authors and editors Downloads Our
More informationOUTCOME OF ACUTE MYELOID LEUKEMIA IN PATIENTS UP TO 65 YEARS OF AGE AT HEMATOLOGY AND BONE MARROW TRANSPLANTATION UNIT IN ALGIERS DURING 14 YEARS
OUTCOME OF ACUTE MYELOID LEUKEMIA IN PATIENTS UP TO 65 YEARS OF AGE AT HEMATOLOGY AND BONE MARROW TRANSPLANTATION UNIT IN ALGIERS DURING 14 YEARS S.Akhrouf, F.Belhadri, A.Talbi, H.Moussaoui, M.Benakli,
More informationHematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia
Medical Policy Manual Transplant, Policy No. 45.36 Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia Next Review: October 2018 Last Review: November 2017 Effective: January 1, 2018 IMPORTANT
More information